Here are the DEF 14A proxy statements from OneMedNet Corp (ONMD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ONMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONMD filings page.
OneMedNet Corporation (ONMD) is asking stockholders at its fully virtual 2026 annual meeting on September 18, 2026 to approve several key items. Stockholders will vote to elect three Class III directors (Kenneth Alleyne, Sherry Coonse McCraw, and Jeffrey Yu) to three-year terms, ratify WithumSmith+Brown, PC as independent auditor for 2026, approve an amendment and restatement of the 2022 Equity Incentive Plan adding 1,000,000 shares to the share reserve, and authorize the Board to implement a reverse stock split at a ratio between 1-for-5 and 1-for-20.
As of August 11, 2026, OneMedNet had 59,286,450 shares of common stock outstanding and was out of compliance with Nasdaq’s $1.00 minimum bid price requirement, with a cure period running until October 12, 2026. The Board states that a reverse split may be used to help regain compliance and maintain the Nasdaq Capital Market listing. The equity plan currently has 826,417 shares available and 4,217,303 shares subject to outstanding RSUs, and the company estimates the newly requested plan shares equal about 1.7% of outstanding stock.
OneMedNet Corporation will hold its 2025 Annual Meeting on December 17, 2025 at 11:00 a.m. CT via live audio webcast at https://www.cstproxy.com/onemednet/2025. Stockholders will vote to elect two Class II directors for three-year terms and to ratify WithumSmith+Brown, PC as independent auditor for 2025.
Holders of record on October 23, 2025 may vote; there were 51,157,069 shares of common stock outstanding as of that date. The Board recommends voting FOR both director nominees and FOR auditor ratification. Director Jair Clarke will not stand for re-election; the Board size will be reduced to eight after the meeting.
The Audit Committee reports Withum fees of $840,000 for 2024 (including $790,000 audit and $50,000 tax). BF Borgers was dismissed in May 2024 following an SEC order; its 2023 report included a going concern explanatory paragraph and noted material weaknesses, with no disagreements reported.
Executive updates include RSU awards to leadership and related-party financings and conversions in 2025 involving Dr. Thomas Kosasa and Dr. Jeffrey Yu. As of October 23, 2025, beneficial ownership includes Dr. Kosasa at 30.8% and Dr. Yu at 13.8%.